Clinical trials: Malignant Tumor With Metastasis
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers
This phase I trial studies the side effects and best dose of sapanisertib and metformin in treating patients with cancers that have spread to other parts of the body (advanced/metastatic), have come back (recurrent), or do not…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Neoplasm
- Trial name
- NCT03017833
- Testing
- Laboratory Biomarker Analysis, Metformin, Pharmacological Study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Kidney Neoplasms
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of…
- Conditions
- Melanoma, Kidney Neoplasms, Metastases
- Trial name
- NCT00095108
- Testing
- Recombinant Human Interleukin-21
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- ZymoGenetics
Stage IV Melanoma, Stage III Melanoma
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will…
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
- Trial name
- NCT00003647
- Testing
- allovectin-7, allovectin-7/dacarbazine, dacarbazine
- Where
- 44 sites in United States
- Sponsor
- Vical
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004243
- Testing
- docetaxel, oxaliplatin
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Breast Cancer, Hormone Receptor Positive Tumor
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer
Breast cancer is rarely curable after metastasis, and the therapeutic options are limited. Interestingly, the host immune response is strongly predictive for the effect of chemotherapy in subgroups of patients with breast cancer.
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Metastatic Breast Cancer
- Trial name
- ICON (NCT03409198)
- Testing
- Ipilimumab, Nivolumab, Pegylated liposomal doxorubicin
- Where
- 6 sites in Belgium, Norway
- Volunteers
- 82 people
- Sponsor
- Oslo University Hospital
Breast Cancer
CIrCuLAting Dna ESr1 Gene Mutations Analysis
The estrogen-dependent nature of breast cancer was first reported in 1896 with the publication of George Beatson's observations on the regression of breast cancer following oophorectomy.
- Trial name
- CICLADES (NCT03318263)
- Testing
- next-generation sequencing (NGS)
- Where
- 10 sites in France
- Volunteers
- 146 people
- Sponsor
- Institut de Cancérologie de Lorraine
Delirium, Locally Advanced Malignant Neoplasm
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
This phase II/IIII trial studies how well haloperidol and lorazepam work in controlling symptoms of persistent agitated delirium in patients with cancer that has spread to other places in the body undergoing palliative care.
- Conditions
- Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
- Trial name
- NCT03743649
- Testing
- Haloperidol, Lorazepam, Quality-of-Life Assessment
- Where
- 3 sites in United States, Brazil
- Volunteers
- 110 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors.
- Trial name
- NCT03030378
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 27 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
This is an open-label, dose escalation study of intravenous ARQ 621 administered to patients with late-stage solid tumors or hematologic malignancies.
- Trial name
- NCT00825487
- Testing
- ARQ 621
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
The investigators hypothesize that combination anlotinib with toripalimab will improve progression-free survival relative to historical controls in patients with Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma.
- Trial name
- NCT03946943
- Testing
- Anlotinib, Toripalimab, Blood Draw
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Di Wu
Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma
The purpose of this study is to evaluate the feasibility, safety and tolerability of locoregional or systemic administration of autologous tumor infiltrating lymphocytes in patients with metastatic melanoma
- Trial name
- GoTIL-01 (NCT07183852)
- Testing
- Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2
- Volunteers
- 18 people
- Sponsor
- Vastra Gotaland Region
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma
Phase I trial to study the effectiveness of vaccine therapy in treating patients who have unresectable metastatic melanoma. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00004148
- Testing
- recombinant vaccinia-B7.1 vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lung Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from…
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes
- Trial name
- NCT00398138
- Testing
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC
- Conditions
- Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic, Adenocarcinoma of Lung, EGFR Wildtype
- Trial name
- NCT02946216
- Testing
- ctDNA analysis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First People's Hospital of Hangzhou
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Carmustine Implants in Treating Patients With Brain Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003878
- Testing
- polifeprosan 20 with carmustine implant, conventional surgery
- Where
- 11 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
In the core study, participants with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit were treated with either 400 mg or 600 mg imatinib mesylate for 3 years.
- Trial name
- NCT00237185
- Testing
- Imatinib mesylate
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Liver Metastases, Colorectal Cancer
The Role of Tumor-associated Macrophages in Colorectal Liver Metastases
Colorectal cancer is a major cause of mortality worldwide. Most patients develop colorectal liver metastases (CLM), and for such patients hepatectomy combined with chemotherapy may be curative.
- Conditions
- Colorectal Liver Metastases, Colorectal Cancer, Liver Metastases, Immunotherapy
- Trial name
- NCT03888638
- Testing
- Hepatectomy
- Volunteers
- 101 people
- Sponsor
- Humanitas Clinical and Research Center
Cancer
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
This is a phase I, open-label, single-arm, single-center, dose-escalation study to evaluate the safety, tolerability, and preliminary anti-tumor efficacy of PAN-NeoVax, an artificial intelligence (AI)-designed pan-cancer…
- Trial name
- NCT07560943
- Testing
- PAN-NeoVax (25 μg), PAN-NeoVax (50 μg), PAN-NeoVax (100 μg)
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Unspecified Adult Solid Tumor, Protocol Specific
Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies
This phase I trial is studying the side effects, best way to give, and best dose of gamma-secretase inhibitor RO4929097 in treating patients with metastatic or unresectable solid malignancies.
- Trial name
- NCT01096355
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacogenomic studies
- Where
- 3 sites in Canada
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT05276609
- Testing
- HS-20093 (Phase Ia: Dose escalation), HS-20093 (Phase Ib: Dose expansion)
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.